
Massimo Rugge

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2719922/publications.pdf Version: 2024-02-01



MASSIMO RUCCE

#	Article	IF	CITATIONS
1	Outcomes of SARS-CoV-2 infection in cancer versus non-cancer-patients: a population-based study in northeastern Italy. Tumori, 2023, 109, 38-46.	0.6	4
2	Autoimmune gastritis: long-term natural history in naÃ⁻ve <i>Helicobacter pylori</i> -negative patients. Gut, 2023, 72, 30-38.	6.1	39
3	Non-compliance with colonoscopy after a positive faecal immunochemical test doubles the risk of dying from colorectal cancer. Gut, 2022, 71, 561-567.	6.1	37
4	Abnormal umbilical cord insertions in singleton deliveries: placental histology and neonatal outcomes. Journal of Clinical Pathology, 2022, 75, 751-758.	1.0	12
5	Pepsinogen II in gastritis and <i>Helicobacter pylori</i> infection. Helicobacter, 2022, 27, e12872.	1.6	13
6	Sex Differences in Cutaneous Melanoma: Incidence, Clinicopathological Profile, Survival, and Costs. Journal of Women's Health, 2022, 31, 1012-1019.	1.5	8
7	Big Data on Gastric Dysplasia Support Gastric Cancer Prevention. Clinical Gastroenterology and Hepatology, 2022, 20, 1226-1228.	2.4	7
8	Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling. Frontiers in Endocrinology, 2022, 13, 834075.	1.5	5
9	Cutaneous Melanoma in Alpine Population: Incidence Trends and Clinicopathological Profile. Current Oncology, 2022, 29, 2165-2173.	0.9	5
10	Malignant Melanoma: Direct Costs by Clinical and Pathological Profile. Dermatology and Therapy, 2022, 12, 1157-1165.	1.4	3
11	Prevalence of Gastric Intestinal Metaplasia in a Multiethnic US Veterans Population. Clinical Gastroenterology and Hepatology, 2021, 19, 269-276.e3.	2.4	17
12	Prevalence of Barrett's esophagus and performance of societalÂscreening guidelines in an unreferred primary care population of U.S. veterans. Gastrointestinal Endoscopy, 2021, 93, 409-419.e1.	0.5	34
13	Prognostic Role of Mismatch Repair Status, Histotype and High-Risk Pathologic Features in Stage II Small Bowel Adenocarcinomas. Annals of Surgical Oncology, 2021, 28, 1167-1177.	0.7	19
14	Diagnosis of digestive system tumours. International Journal of Cancer, 2021, 148, 1040-1050.	2.3	36
15	Histological assessment of gastric pseudopyloric metaplasia: Intra- and inter-observer consistency. Digestive and Liver Disease, 2021, 53, 61-65.	0.4	9
16	Ethics in clinical autopsy. Journal of Clinical Pathology, 2021, 74, 339-343.	1.0	3
17	Midâ€ŧerm trends and recent birthâ€cohortâ€dependent changes in incidence rates of cutaneous malignant melanoma in Italy. International Journal of Cancer, 2021, 148, 835-844.	2.3	13
18	More Favorable Short and Long-Term Outcomes for Screen-Detected Colorectal Cancer Patients. Frontiers in Oncology, 2021, 11, 620644.	1.3	8

#	Article	IF	CITATIONS
19	Objective Evidence of Gastro-Esophageal Reflux Disease is Rare in Patients with Autoimmune Gastritis. Journal of Gastrointestinal and Liver Diseases, 2021, 30, 30-36.	0.5	2
20	Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides. Nature Communications, 2021, 12, 2255.	5.8	37
21	Prognostic relevance and putative histogenetic role of cytokeratin 7 and MUC5AC expression in Crohn's disease-associated small bowel carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 667-678.	1.4	10
22	Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients who underwent antiestrogenic therapy. Annals of Oncology, 2021, 32, 676-677.	0.6	17
23	Colorectal cancer incidence and mortality after negative fecal immunochemical tests by age 70: A prospective observational study. International Journal of Cancer, 2021, 149, 1257-1265.	2.3	3
24	United we win: Pushing for follow up after a positive faecal immunochemical test. Digestive and Liver Disease, 2021, 53, 1058.	0.4	0
25	Gastritis: The clinico-pathological spectrum. Digestive and Liver Disease, 2021, 53, 1237-1246.	0.4	30
26	SARS-CoV-2 Infection in Cancer Patients: A Population-Based Study. Frontiers in Oncology, 2021, 11, 730131.	1.3	11
27	Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study. Frontiers in Oncology, 2021, 11, 737399.	1.3	14
28	Quality management of cutaneous melanoma: impact on short-term outcomes and costs. European Journal of Dermatology, 2021, 31, 730-735.	0.3	3
29	Not All Autoimmune Gastritis Are Created the Same. Gastroenterology Research, 2021, 14, 348-349.	0.4	4
30	Cholecystectomy during esophagectomy is safe but unnecessary. Acta Chirurgica Belgica, 2020, 120, 35-41.	0.2	1
31	Secondary prevention of gastric cancer: merging the endoscopic atrophic border with OLGA staging. Gut, 2020, 69, 1151-1152.	6.1	9
32	Separation of Low- Versus High-grade Crohn's Disease-associated Small Bowel Carcinomas is Improved by Invasive Front Prognostic Marker Analysis. Journal of Crohn's and Colitis, 2020, 14, 295-302.	0.6	14
33	The 2019 WHO classification of tumours of the digestive system. Histopathology, 2020, 76, 182-188.	1.6	1,952
34	<i>Helicobacter pylori</i> heteroresistance to clarithromycin in adults—New data by in situ detection and improved concept. Helicobacter, 2020, 25, e12670.	1.6	21
35	PD-L1 expression in gastroesophageal dysplastic lesions. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 151-156.	1.4	24
36	Gastric cancer risk: between genetics and lifestyle. Lancet Oncology, The, 2020, 21, 1258-1260.	5.1	12

#	Article	IF	CITATIONS
37	Genetic and hormonal influence on SARS-CoV-2-infection susceptibility. Annals of Oncology, 2020, 31, 1584-1585.	0.6	2
38	Reply to the Letter to the Editor "Androgen deprivation therapy may constitute a more effective prophylactic than therapeutic strategy in COVID-19 patients―by N. Bennani and I.ÂM.ÂBennani-Baiti. Annals of Oncology, 2020, 31, 1586-1587.	0.6	2
39	Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages. Cancer Discovery, 2020, 10, 1758-1773.	7.7	44
40	Gastritis Stages in Monozygotic and Dizygotic Dyspeptic Twins. Gastroenterology Research and Practice, 2020, 2020, 1-5.	0.7	2
41	Patterns of care and cost profiles of women with breast cancer in Italy: EPICOST study based on real world data. European Journal of Health Economics, 2020, 21, 1003-1013.	1.4	12
42	Small Bowel Adenocarcinomas Featuring Special AT-Rich Sequence-Binding Protein 2 (SATB2) Expression and a Colorectal Cancer-Like Immunophenotype: A Potential Diagnostic Pitfall. Cancers, 2020, 12, 3441.	1.7	10
43	SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer. Nature Cancer, 2020, 1, 784-788.	5.7	86
44	White Adipose Tissue Expansion in Multiple Symmetric Lipomatosis Is Associated with Upregulation of CK2, AKT and ERK1/2. International Journal of Molecular Sciences, 2020, 21, 7933.	1.8	8
45	Immune surveillance activation after neoadjuvant therapy for esophageal adenocarcinoma and complete response. Oncolmmunology, 2020, 9, 1804169.	2.1	5
46	Gastritis: An Update in 2020. Current Treatment Options in Gastroenterology, 2020, 18, 488-503.	0.3	7
47	Allelic Imbalance Analysis in Liquid Biopsy to Monitor Locally Advanced Esophageal Cancer Patients During Treatment. Frontiers in Oncology, 2020, 10, 1320.	1.3	3
48	Biologic profiles meet clinical priorities: incorporating pseudopyloric, and spasmolytic-expressing metaplasia in the assessment of gastric atrophy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 487-488.	1.4	7
49	Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (NÂ= 4532). Annals of Oncology, 2020, 31, 1040-1045.	0.6	447
50	There is much more to rely on histology than the sole endoscopy tells us. Gut, 2020, 69, 1709-1710.	6.1	2
51	Bright future for endoscopy: the new frontier of gastric cancer secondary prevention. Gut, 2020, 69, 1723-1724.	6.1	3
52	Colonoscopy later than 270 days in a fecal immunochemical test-based population screening program is associated with higher prevalence of colorectal cancer. Endoscopy, 2020, 52, 871-876.	1.0	27
53	Histology of pediatric classic Hodgkin lymphoma: From diagnosis to prognostic stratification. Pediatric Blood and Cancer, 2020, 67, e28230.	0.8	2
54	Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrett's carcinogenesis. Pathology Research and Practice, 2020, 216, 152907.	1.0	17

#	Article	IF	CITATIONS
55	Autoimmune gastritis. Nature Reviews Disease Primers, 2020, 6, 56.	18.1	156
56	High prevalence of human papillomavirus infection in sinonasal inverted papilloma: a singleâ€institution cohort of patients. International Forum of Allergy and Rhinology, 2020, 10, 629-635.	1.5	6
5 7	PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability. Modern Pathology, 2020, 33, 1398-1409.	2.9	35
58	Decline in the incidence of colorectal cancer and the associated mortality in young Italian adults. Gut, 2020, 69, 1902-1903.	6.1	9
59	Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. Oncologist, 2020, 25, 481-487.	1.9	77
60	Synchronous nodal metastatic risk in screening detected and endoscopically removed pT1 colorectal cancers. Pathology Research and Practice, 2020, 216, 152966.	1.0	8
61	Incidence trends of vulvar squamous cell carcinoma in Italy from 1990 to 2015. Gynecologic Oncology, 2020, 157, 656-663.	0.6	19
62	Gastrointestinal tissueâ€based molecular biomarkers: a practical categorisation based on the 2019 World Health Organization classification of epithelial digestive tumours. Histopathology, 2020, 77, 340-350.	1.6	26
63	Peptidomic and proteomic analysis of stool for diagnosing IBD and deciphering disease pathogenesis. Clinical Chemistry and Laboratory Medicine, 2020, 58, 968-979.	1.4	11
64	Gastritis: update on etiological features and histological practical approach. Pathologica, 2020, 112, 153-165.	1.3	24
65	COLORECTAL CANCER INCIDENCE AND MORTALITY IN SUBJECTS WITH POSITIVE FAECAL IMMUNOCHEMICAL BLOOD TEST WHO DO NOT ATTEND SCREENING COLONOSCOPY. Endoscopy, 2020, 52, .	1.0	0
66	Characterization of subcutaneous and omental adipose tissue in patients with obesity and with different degrees of glucose impairment. Scientific Reports, 2019, 9, 11333.	1.6	48
67	<p>Programmed cell death 4 (PDCD4) as a novel prognostic marker for papillary thyroid carcinoma</p> . Cancer Management and Research, 2019, Volume 11, 7845-7855.	0.9	6
68	Pathological Tumor Regression Grade Classifications in Gastrointestinal Cancers: Role on Patients' Prognosis. International Journal of Surgical Pathology, 2019, 27, 816-835.	0.4	8
69	PD‣1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus. Cancer Medicine, 2019, 8, 6036-6048.	1.3	23
70	Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status. , 2019, 7, 297.		24
71	Silencing of miR-182 is associated with modulation of tumorigenesis through apoptosis induction in an experimental model of colorectal cancer. BMC Cancer, 2019, 19, 821.	1.1	22
72	CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer. British Journal of Cancer, 2019, 121, 593-599.	2.9	24

#	Article	IF	CITATIONS
73	CD80 expression promotes immune surveillance in Barrett's metaplasia. Oncolmmunology, 2019, 8, e1636618.	2.1	3
74	Protein kinase C inhibitors override ZEB1-induced chemoresistance in HCC. Cell Death and Disease, 2019, 10, 703.	2.7	25
75	Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. British Journal of Cancer, 2019, 121, 257-263.	2.9	53
76	Consistency and reproducibility of nextâ€generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. Cancer Cytopathology, 2019, 127, 285-296.	1.4	39
77	Squamous cell carcinoma antigen 1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity. Cancer Science, 2019, 110, 1552-1563.	1.7	21
78	Failure to rescue as a source of variation in hospital mortality after rectal surgery: The Italian experience. European Journal of Surgical Oncology, 2019, 45, 1219-1224.	0.5	8
79	miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial. Clinical Cancer Research, 2019, 25, 3830-3838.	3.2	42
80	Class 1, 2, and 3 <i>BRAF</i> -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. Clinical Cancer Research, 2019, 25, 3954-3961.	3.2	67
81	Trends of colorectal cancer incidence and mortality rates from 2003 to 2014 in Italy. Tumori, 2019, 105, 417-426.	0.6	15
82	Periodontal Injection of Lipopolysaccharide Promotes Arthritis Development in Mice. Inflammation, 2019, 42, 1117-1128.	1.7	12
83	Molecular characterization of "sessile serrated―adenoma to carcinoma transition in six early colorectal cancers. Pathology Research and Practice, 2019, 215, 957-962.	1.0	11
84	Gastric cancer prevention targeted on risk assessment: Gastritis OLGA staging. Helicobacter, 2019, 24, e12571.	1.6	20
85	Weak Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis. Clinical and Translational Gastroenterology, 2019, 10, e00061.	1.3	2
86	Another Chapter of the Right Versus Left Story : Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer?. Oncologist, 2019, 24, e77-e79.	1.9	3
87	Diagnosis. Current Opinion in Gastroenterology, 2019, 35, 535-543.	1.0	28
88	Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells. Melanoma Research, 2019, 29, 89-94.	0.6	4
89	Human papillomavirus infection is not involved in esophageal verrucous carcinoma. Human Pathology, 2019, 85, 50-57.	1.1	10
90	miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. Translational Oncology, 2019, 12, 282-291.	1.7	14

#	Article	IF	CITATIONS
91	Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma. Human Pathology, 2019, 85, 251-259.	1.1	6
92	Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut, 2019, 68, 11-17.	6.1	132
93	Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives. World Journal of Gastroenterology, 2019, 25, 5773-5788.	1.4	69
94	The rising incidence of papillary thyroid cancer: More cancers or more assessments?. Indian Journal of Cancer, 2019, 56, 183.	0.2	5
95	Papilloma virus infection in oral malignancies: An Italian experience. Indian Journal of Cancer, 2019, 56, 279.	0.2	0
96	Do Not Leave FIT Positives Alone!. American Journal of Gastroenterology, 2018, 113, 913.	0.2	2
97	Onycholemmal carcinoma: A case report with its molecular profiling. Journal of Cutaneous Pathology, 2018, 45, 463-465.	0.7	3
98	Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37â€^513â€`025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, The, 2018, 391, 1023-1075.	6.3	3,228
99	Interval Cancers in Colorectal Cancer Screening Programs. Gastroenterology, 2018, 154, 762-763.	0.6	0
100	Letter: gastric atrophy assessment—merging serology, endoscopy and histology in clinical practice. Alimentary Pharmacology and Therapeutics, 2018, 47, 151-152.	1.9	3
101	Haploidentical stem cell transplantation cures autoimmune hepatitis and cerebrovascular disease in a patient with sickle cell disease. Bone Marrow Transplantation, 2018, 53, 644-646.	1.3	7
102	Study of diagnostic accuracy of Fagan's two-step nomogram in increasing the value of predictive tools for prostate cancer: application of specific spatial distribution of positive/negative bioptic cores to predict extracapsular extension. Aging Clinical and Experimental Research, 2018, 30, 1497-1504.	1.4	3
103	Time to diagnosis in esophageal cancer: a cohort study. Acta Oncológica, 2018, 57, 1179-1184.	0.8	14
104	Long-Standing Ulcerative Colitis May Trigger a Multilineage Cancerization Field. International Journal of Surgical Pathology, 2018, 26, 558-560.	0.4	0
105	miR-194 as predictive biomarker of responsiveness to neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma. Journal of Clinical Pathology, 2018, 71, 344-350.	1.0	29
106	Long-term performance of colorectal cancer screening programmes based on the faecal immunochemical test. Gut, 2018, 67, 2124-2130.	6.1	57
107	A lucky mistake: the splenic glands of Marcello Malpighi. Human Pathology, 2018, 72, 191-195.	1.1	3
108	Gastritis staging as a clinical priority. European Journal of Gastroenterology and Hepatology, 2018, 30, 125-129.	0.8	12

#	Article	IF	CITATIONS
109	Decellularized colorectal cancer matrix as bioactive microenvironment for in vitro 3D cancer research. Journal of Cellular Physiology, 2018, 233, 5937-5948.	2.0	61
110	Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. Gut, 2018, 67, 1484-1492.	6.1	59
111	Divergent Long-Term Detection Rates of Proximal and Distal Advanced Neoplasia in Fecal Immunochemical Test Screening Programs. Annals of Internal Medicine, 2018, 169, 602.	2.0	35
112	Clear cell dysplasia in a sessile serrated adenoma. Pathology Research and Practice, 2018, 214, 2121-2122.	1.0	1
113	OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients. American Journal of Gastroenterology, 2018, 113, 1621-1628.	0.2	96
114	Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. Cancer Cell International, 2018, 18, 131.	1.8	7
115	Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. Cancer Discovery, 2018, 8, 1270-1285.	7.7	187
116	Benign TdT-positive cells in pediatric and adult lymph nodes: a potential diagnostic pitfall. Human Pathology, 2018, 81, 131-137.	1.1	6
117	The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes. European Journal of Cancer, 2018, 101, 191-200.	1.3	86
118	Hyperinsulinemia Promotes Esophageal Cancer Development in a Surgically-Induced Duodeno-Esophageal Reflux Murine Model. International Journal of Molecular Sciences, 2018, 19, 1198.	1.8	13
119	RORγt-Expressing Tregs Drive the Growth of Colitis-Associated Colorectal Cancer by Controlling IL6 in Dendritic Cells. Cancer Immunology Research, 2018, 6, 1082-1092.	1.6	35
120	A coordinate deregulation of microRNAs expressed in mucosa adjacent to tumor predicts relapse after resection in localized colon cancer. Molecular Cancer, 2018, 17, 17.	7.9	15
121	Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1926-1935.	1.4	30
122	MiR-21 up-regulation in ampullary adenocarcinoma and its pre-invasive lesions. Pathology Research and Practice, 2018, 214, 835-839.	1.0	26
123	Prevalence of ALK gene alterations among the spectrum of plexiform spitzoid lesions. Journal of the American Academy of Dermatology, 2018, 79, 728-735.	0.6	10
124	Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?. Journal of Clinical Oncology, 2018, 36, 3590-3590.	0.8	4
125	The evolution of the epidemiological landscape of head and neck cancer in Italy: Is there evidence for an increase in the incidence of potentially HPV-related carcinomas?. PLoS ONE, 2018, 13, e0192621.	1.1	58
126	Levels of miR-126 and miR-218 are elevated in ductal carcinoma <i>in situ</i> (DCIS) and inhibit malignant potential of DCIS derived cells. Oncotarget, 2018, 9, 23543-23553.	0.8	12

#	Article	IF	CITATIONS
127	Monitoring advanced non-small cell lung cancer (NSCLC) through plasma genotyping during systemic treatment: KRAS-mutated (m) cohort results Journal of Clinical Oncology, 2018, 36, e24074-e24074.	0.8	0
128	Peptic Ulcer Disease and <i>Helicobacter pylori</i> Infection in Different Siberian Ethnicities. Helicobacter, 2017, 22, e12322.	1.6	8
129	Clinical Manifestations of Helicobacter pylori–Negative Gastritis. Clinical Gastroenterology and Hepatology, 2017, 15, 1037-1046.e3.	2.4	40
130	Insulin promotes HER2 signaling activation during Barrett's Esophagus carcinogenesis. Digestive and Liver Disease, 2017, 49, 630-638.	0.4	8
131	The molecular landscape of colitis-associated carcinogenesis. Digestive and Liver Disease, 2017, 49, 326-330.	0.4	34
132	Mismatch Repair Deficiency, Microsatellite Instability, and Survival. JAMA Oncology, 2017, 3, 1197.	3.4	398
133	Absence of Neurofibromin Induces an Oncogenic Metabolic Switch via Mitochondrial ERK-Mediated Phosphorylation of the Chaperone TRAP1. Cell Reports, 2017, 18, 659-672.	2.9	81
134	<scp>PD</scp> ‣1 overexpression in ampulla of Vater carcinoma and its preâ€invasive lesions. Histopathology, 2017, 71, 470-474.	1.6	27
135	Pigmented trichoblastoma developed in a sebaceous nevus: HRAS mutation as a common molecular driver. Pathology Research and Practice, 2017, 213, 860-862.	1.0	4
136	Tumor budding as a risk factor for nodal metastasis in pT1 colorectal cancers: a meta-analysis. Human Pathology, 2017, 65, 62-70.	1.1	70
137	Gastric Cancer as Preventable Disease. Clinical Gastroenterology and Hepatology, 2017, 15, 1833-1843.	2.4	162
138	Aberrant expression of <scp>CD</scp> 10 and <scp>BCL</scp> 6 in mantle cell lymphoma. Histopathology, 2017, 71, 769-777.	1.6	29
139	Adenosquamous gallbladder carcinoma: Multigene hotspot mutational profiling reveals a monoclonal origin of the two components. Pathology Research and Practice, 2017, 213, 1010-1013.	1.0	6
140	Early miR-223 Upregulation in Gastroesophageal Carcinogenesis. American Journal of Clinical Pathology, 2017, 147, 301-308.	0.4	23
141	Small Bowel Carcinomas in Coeliac or Crohn's Disease: Clinico-pathological, Molecular, and Prognostic Features. A Study From the Small Bowel Cancer Italian Consortium. Journal of Crohn's and Colitis, 2017, 11, 942-953.	0.6	51
142	Colonic metaplasia of the neo-terminal ileum in Crohn's Disease. Digestive and Liver Disease, 2017, 49, 451.	0.4	0
143	In-hospital mortality, 30-day readmission, and length of hospital stay after surgery for primary colorectal cancer: A national population-based study. European Journal of Surgical Oncology, 2017, 43, 1312-1323.	0.5	38
144	Management of <i>Helicobacter pylori</i> infection—the Maastricht V/Florence Consensus Report. Gut, 2017, 66, 6-30.	6.1	2,245

#	Article	IF	CITATIONS
145	Detection of genetic alterations in cfDNA as a possible strategy to monitor the neoplastic progression of Barrett's esophagus. Translational Research, 2017, 190, 16-24.e1.	2.2	15
146	Immunonutrition before esophagectomy: Impact on immune surveillance mechanisms. Tumor Biology, 2017, 39, 101042831772868.	0.8	8
147	Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy. Clinical Cancer Research, 2017, 23, 7543-7549.	3.2	12
148	Diagnosis and Endoscopic Management of Barrett's Esophagus: an Italian Experts' Opinion based document. Digestive and Liver Disease, 2017, 49, 1306-1313.	0.4	7
149	MiR-375 and YAP1 expression profiling in medullary thyroid carcinoma and their correlation with clinical–pathological features and outcome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 651-658.	1.4	25
150	BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling. Histopathology, 2017, 71, 1008-1011.	1.6	8
151	Antibioticâ€induced dysbiosis of the microbiota impairs gut neuromuscular function in juvenile mice. British Journal of Pharmacology, 2017, 174, 3623-3639.	2.7	82
152	Epstein-Barr virus-positive ileal carcinomas associated with Crohn's disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 549-552.	1.4	12
153	Esophageal adenocarcinoma microenvironment: Peritumoral adipose tissue effects associated with chemoresistance. Cancer Science, 2017, 108, 2393-2404.	1.7	11
154	Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study. Lancet Oncology, The, 2017, 18, 1022-1039.	5.1	285
155	Nodal skip metastasis in thoracic esophageal squamous cell carcinoma: a cohort study. BMC Surgery, 2017, 17, 49.	0.6	14
156	Small bowel carcinomas in celiac or Crohn's disease: distinctive histophenotypic, molecular and histogenetic patterns. Modern Pathology, 2017, 30, 1453-1466.	2.9	40
157	Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers. PLoS ONE, 2017, 12, e0189953.	1.1	27
158	Squamous cell carcinoma antigen (SCCA) is up-regulated during Barrett's carcinogenesis and predicts esophageal adenocarcinoma resistance to neoadjuvant chemotherapy. Oncotarget, 2017, 8, 24372-24379.	0.8	10
159	Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. Oncotarget, 2017, 8, 32626-32638.	0.8	14
160	Chronicles of a cancer foretold: 35â€years of gastric cancer risk assessment. Gut, 2016, 65, 721-725.	6.1	72
161	Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer. BMC Cancer, 2016, 16, 312.	1.1	21
162	A pH-sensitive stearoyl-PEG-poly(methacryloyl sulfadimethoxine)-decorated liposome system for protein delivery: An application for bladder cancer treatment. Journal of Controlled Release, 2016, 238, 31-42.	4.8	75

#	Article	IF	CITATIONS
163	MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. British Journal of Cancer, 2016, 115, 1343-1350.	2.9	27
164	Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. Journal of Clinical Oncology, 2016, 34, 2721-2727.	0.8	214
165	Liquid biopsy as a novel tool to monitor the carcinogenesis of Barrett's esophagus. Translational Research, 2016, 176, 127-131.	2.2	7
166	Immunohistochemical expression of p16 in lipoblastomas. Human Pathology, 2016, 47, 64-69.	1.1	21
167	Early signet ring cell carcinoma arising from colonic adenoma: the molecular profiling supports the adenoma-carcinoma sequence. Human Pathology, 2016, 50, 183-186.	1.1	8
168	Differential timing of oxidative DNA damage and telomere shortening in hepatitis C and B virus–related liver carcinogenesis. Translational Research, 2016, 168, 122-133.	2.2	19
169	Genetic risk of subsequent esophageal cancer in lymphoma and breast cancer long-term survival patients: a pilot study. Pharmacogenomics Journal, 2016, 16, 266-271.	0.9	4
170	Adherence to WCRF/AICR lifestyle recommendations for cancer prevention and the risk of Barrett's esophagus onset and evolution to esophageal adenocarcinoma: results from a pilot study in a high-risk population. European Journal of Nutrition, 2016, 55, 1563-1571.	1.8	13
171	Grp94 in complexes with IgG is a soluble diagnostic marker of gastrointestinal tumors and displays immune-stimulating activity on peripheral blood immune cells. Oncotarget, 2016, 7, 72923-72940.	0.8	11
172	Let-7c down-regulation in <i>Helicobacter pylori</i> -related gastric carcinogenesis. Oncotarget, 2016, 7, 4915-4924.	0.8	26
173	Aberrant gene methylation in non-neoplastic mucosa as a predictive marker of ulcerative colitis-associated CRC. Oncotarget, 2016, 7, 10322-10331.	0.8	29
174	Serum miR-125b is a non-invasive predictive biomarker of the pre-operative chemoradiotherapy responsiveness in patients with rectal adenocarcinoma. Oncotarget, 2016, 7, 28647-28657.	0.8	61
175	Metastatic colorectal cancer (mCRC) treatment: A high-volume, single-center, real-life experience Journal of Clinical Oncology, 2016, 34, 733-733.	0.8	0
176	Benign mesothelial cells in lymph nodes and lymphatic spaces associated with ascites. Histology and Histopathology, 2016, 31, 747-50.	0.5	3
177	From Barrett metaplasia to esophageal adenocarcinoma: the molecular background. Histology and Histopathology, 2016, 31, 25-32.	0.5	13
178	Autoimmune gastritis: Pathologist's viewpoint. World Journal of Gastroenterology, 2015, 21, 12179.	1.4	149
179	Atrophic Gastritis in the Arctic. Clinical Gastroenterology and Hepatology, 2015, 13, 1601-1603.	2.4	2
180	Gastrointestinal Crohn-like disease following BCG therapy. International Journal of Colorectal Disease, 2015, 30, 1745-1746.	1.0	3

#	Article	IF	CITATIONS
181	Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. Digestive and Liver Disease, 2015, 47, 903-912.	0.4	106
182	Gastric Cancer Risk in Patients with Helicobacter pylori Infection and Following Its Eradication. Gastroenterology Clinics of North America, 2015, 44, 609-624.	1.0	21
183	Epidemiology of Gastric Cancer. , 2015, , 23-34.		85
184	HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases. Human Pathology, 2015, 46, 665-672.	1.1	47
185	BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. British Journal of Cancer, 2015, 112, 1921-1928.	2.9	146
186	Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer. Endoscopy International Open, 2015, 03, E165-E170.	0.9	44
187	Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 2015, 47, 829-854.	1.0	1,112
188	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Modern Pathology, 2015, 28, 1481-1491.	2.9	226
189	The stomach in health and disease. Gut, 2015, 64, 1650-1668.	6.1	283
190	The PDCD4/miR-21 pathway in medullary thyroid carcinoma. Human Pathology, 2015, 46, 50-57.	1.1	66
191	<i>In vivo</i> molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma. Ecological Management and Restoration, 2015, 28, 394-403.	0.2	22
192	Definition of Barrett's Esophagus Dysplasia: Are We Speaking the Same Language?. World Journal of Surgery, 2015, 39, 559-565.	0.8	5
193	Genetic Features of Metachronous Esophageal Cancer Developed in Hodgkin's Lymphoma or Breast Cancer Long-Term Survivors: An Exploratory Study. PLoS ONE, 2015, 10, e0117070.	1.1	8
194	A GFP-Tagged Gross Deletion on Chromosome 1 Causes Malignant Peripheral Nerve Sheath Tumors and Carcinomas in Zebrafish. PLoS ONE, 2015, 10, e0145178.	1.1	7
195	CD80-CD28 signaling controls the progression of inflammatory colorectal carcinogenesis. Oncotarget, 2015, 6, 20058-20069.	0.8	24
196	Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. Oncotarget, 2015, 6, 6544-6552.	0.8	31
197	Role of Proton Pump Inhibitor on Esophageal Carcinogenesis and Pancreatic Acinar Cell Metaplasia Development: An Experimental In Vivo Study. PLoS ONE, 2014, 9, e112862.	1.1	18
198	Oxidative damage in the progression of chronic liver disease to hepatocellular carcinoma: An intricate pathway. World Journal of Gastroenterology, 2014, 20, 3078.	1.4	58

#	Article	IF	CITATIONS
199	Molecular diagnostics in gastric cancer. Frontiers in Bioscience - Landmark, 2014, 19, 312.	3.0	25
200	Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis. Oncotarget, 2014, 5, 7162-7171.	0.8	35
201	Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. British Journal of Cancer, 2014, 111, 25-32.	2.9	41
202	Cytokine BAFF Released by Helicobacter pylori–Infected Macrophages Triggers the Th17 Response in Human Chronic Gastritis. Journal of Immunology, 2014, 193, 5584-5594.	0.4	62
203	Beyond scoring: a modern histological assessment of chronic hepatitis should include tissue angiogenesis. Gut, 2014, 63, 1366-1367.	6.1	6
204	Individual risk stratification of gastric cancer: Evolving concepts and their impact on clinical practice. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 1043-1053.	1.0	35
205	Colonic Phenotype of the lleum in Crohn's Disease. Inflammatory Bowel Diseases, 2014, 20, 1555-1561.	0.9	5
206	MicroRNA-135b Promotes Cancer Progression by Acting as a Downstream Effector of Oncogenic Pathways in Colon Cancer. Cancer Cell, 2014, 25, 469-483.	7.7	267
207	Secondary Prevention of Epidemic Gastric Cancer in the Model of <i>Helicobacter pylori</i> -Associated Gastritis. Digestive Diseases, 2014, 32, 265-274.	0.8	17
208	Association between Helicobacter pylori and Barrett's Esophagus: A Case–Control Study. American Journal of Gastroenterology, 2014, 109, 357-368.	0.2	63
209	Human miRNome profiling in colorectal cancer and liver metastasis development. Genomics Data, 2014, 2, 184-188.	1.3	7
210	Helicobacter pylori Infection – The Link Between Oxidative Damage, Cell Proliferation, Apoptosis, and Gastric Cancer. , 2014, , 1871-1891.		0
211	Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression. Oncotarget, 2014, 5, 6611-6619.	0.8	53
212	Esophageal carcinosarcoma: management and prognosis at a single Italian series. Anticancer Research, 2014, 34, 7455-9.	0.5	15
213	Dysplasia in inflammatory bowel diseases. Digestive and Liver Disease, 2013, 45, 186-194.	0.4	22
214	The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples. Translational Oncology, 2013, 6, 10-16.	1.7	47
215	Helicobacter pylori -Negative Gastritis: Prevalence and Risk Factors. American Journal of Gastroenterology, 2013, 108, 65-71.	0.2	72
216	Management of Gastric Polyps: An Endoscopy-Based Approach. Clinical Gastroenterology and Hepatology, 2013, 11, 1374-1384.	2.4	82

#	Article	IF	CITATIONS
217	Precancerous lesions in the stomach: From biology to clinical patient management. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 205-223.	1.0	96
218	"Double Trouble―or an Amplification of the Triploidy Phenotype?. Fetal and Pediatric Pathology, 2013, 32, 60-65.	0.4	2
219	PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 57-63.	1.4	55
220	PDCD4 expression in thyroid neoplasia. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 95-100.	1.4	22
221	Pancreatic mucinous cystic tumor in Turner syndrome: How a tumor bends to a genetic disease. International Journal of Surgery Case Reports, 2013, 4, 1028-1031.	0.2	1
222	Secondary cancer prevention. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 157-158.	1.0	1
223	The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis. Human Pathology, 2013, 44, 1804-1810.	1.1	49
224	Autoimmune atrophic gastritis—pathogenesis, pathology and management. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 529-541.	8.2	285
225	microRNA-145 in Barrett's oesophagus: regulating BMP4 signalling via GATA6. Gut, 2013, 62, 664-675.	6.1	44
226	Letter: gastric cancer and pernicious anaemia – often <i><scp>H</scp>elicobacter pylori</i> in disguise. Alimentary Pharmacology and Therapeutics, 2013, 37, 764-765.	1.9	8
227	The Hyaluronic Acid Receptor CD44 Coordinates Normal and Metaplastic Gastric Epithelial Progenitor Cell Proliferation. Journal of Biological Chemistry, 2013, 288, 16085-16097.	1.6	97
228	MicroRNA Expression Profiling in the Histological Subtypes of Barrett's Metaplasia. Clinical and Translational Gastroenterology, 2013, 4, e34.	1.3	32
229	Retaining the long-survive capacity of Circulating Tumor Cells (CTCs) followed by xeno-transplantation: not only from metastatic cancer of the breast but also of prostate cancer patients. Oncoscience, 2013, 1, 49-56.	0.9	52
230	Apert Syndrome with Fused Thalami. Fetal and Pediatric Pathology, 2012, 31, 410-414.	0.4	7
231	Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scandinavian Journal of Gastroenterology, 2012, 47, 136-147.	0.6	136
232	Re: Risk of Malignant Progression in Barrett's Esophagus Patients: Results from a Large Population-Based Study. Journal of the National Cancer Institute, 2012, 104, 1771-1772.	3.0	12
233	Isolated Tumor Cells in Regional Lymph Nodes as Relapse Predictors in Stage I and II Colorectal Cancer. Journal of Clinical Oncology, 2012, 30, 965-971.	0.8	47
234	Lesions Indefinite for Intraepithelial Neoplasia and OLGA Staging for Gastric Atrophy. American Journal of Clinical Pathology, 2012, 137, 727-732.	0.4	22

#	Article	IF	CITATIONS
235	MicroRNA Dysregulation in Esophageal Neoplasia: The Biological Rationale for Novel Therapeutic Options. Current Pharmaceutical Design, 2012, 19, 1236-1241.	0.9	12
236	Anterior Gradient 2 Overexpression in Lung Adenocarcinoma. Applied Immunohistochemistry and Molecular Morphology, 2012, 20, 31-36.	0.6	26
237	Barrett's Esophagus and Adenocarcinoma Risk. Annals of Surgery, 2012, 256, 788-795.	2.1	45
238	Pathogenesis of <i><scp>H</scp>elicobacter pylori</i> Infection. Helicobacter, 2012, 17, 9-15.	1.6	45
239	Letter: gastric atrophy as a precursor of gastric cancer – authors' reply. Alimentary Pharmacology and Therapeutics, 2012, 36, 605-605.	1.9	0
240	Early HER2 dysregulation in gastric and oesophageal carcinogenesis. Histopathology, 2012, 61, 769-776.	1.6	64
241	Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas. Human Pathology, 2012, 43, 1206-1212.	1.1	34
242	Anterior gradient 2 profiling in Barrett columnar epithelia and adenocarcinoma. Human Pathology, 2012, 43, 1839-1844.	1.1	7
243	Pentalogy of Cantrell with Complete Ectopia Cordis in a Fetus with Asplenia. Pediatric and Developmental Pathology, 2012, 15, 495-498.	0.5	8
244	Secondary prevention of gastric cancer. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 128-129.	8.2	25
245	MicroRNA Profiles in Familial and Sporadic Medullary Thyroid Carcinoma: Preliminary Relationships with RET Status and Outcome. Thyroid, 2012, 22, 890-896.	2.4	116
246	Autoimmune gastritis: histology phenotype and <scp>OLGA</scp> staging. Alimentary Pharmacology and Therapeutics, 2012, 35, 1460-1466.	1.9	101
247	Programmed cell death 4 nuclear loss and miR-21 or activated Akt overexpression in esophageal squamous cell carcinogenesis. Ecological Management and Restoration, 2012, 25, 263-268.	0.2	28
248	Long-Term Follow-up of Barrett's Epithelium: Medical Versus Antireflux Surgical Therapy. Journal of Gastrointestinal Surgery, 2012, 16, 7-15.	0.9	45
249	Quantification of Serum Levels of Pepsinogens and Gastrin to Assess Eradication of Helicobacter Pylori. Clinical Gastroenterology and Hepatology, 2011, 9, 440-442.	2.4	23
250	"Die Grenzen meiner Sprache sind die Grenzen meiner Welt―– Pathologists and their readers. Digestive and Liver Disease, 2011, 43, S279-S281.	0.4	3
251	The war of the worlds: metaplastic versus nonmetaplastic atrophic gastritis. Gastrointestinal Endoscopy, 2011, 73, 411-412.	0.5	3
252	HER-2/neu expression is consistent in primary and metastatic lung adenocarcinoma. Lung Cancer, 2011, 71, 371-372.	0.9	5

#	Article	IF	CITATIONS
253	Operative Link for Gastritis Assessment gastritis staging incorporates intestinal metaplasia subtyping. Human Pathology, 2011, 42, 1539-1544.	1.1	36
254	Gastritis: The histology report. Digestive and Liver Disease, 2011, 43, S373-S384.	0.4	115
255	miRNAs in precancerous lesions of the gastrointestinal tract. World Journal of Gastroenterology, 2011, 17, 5231.	1.4	29
256	Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. World Journal of Gastroenterology, 2011, 17, 4596.	1.4	112
257	Tumor-associated macrophages as major source of APRIL in gastric MALT lymphoma. Blood, 2011, 117, 6612-6616.	0.6	55
258	<i>Helicobacter pylori</i> Infection, Intestinal Metaplasia, and Gastric Cancer Risk in Eastern Siberia. Helicobacter, 2011, 16, 107-112.	1.6	28
259	From Open-Type Atrophic Gastritis to Gastritis Staging. Digestive Diseases and Sciences, 2011, 56, 1917-1918.	1.1	2
260	PDCD4 nuclear loss inversely correlates with miR-21 levels in colon carcinogenesis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 413-419.	1.4	72
261	Gastric type I carcinoid: a pilot study with human G17DT immunogen vaccination. Cancer Immunology, Immunotherapy, 2011, 60, 1057-1060.	2.0	13
262	Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology, 2011, 54, 890-899.	3.6	82
263	MicroRNA expression profiling in human Barrett's carcinogenesis. International Journal of Cancer, 2011, 129, 1661-1670.	2.3	100
264	Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. European Journal of Endocrinology, 2011, 164, 971-976.	1.9	86
265	Clinical Practice: Diagnosis and Evaluation of Dyspepsia. Journal of Clinical Gastroenterology, 2010, 44, 167-172.	1.1	25
266	Somatostatin Receptor Type 2 (SSTR2) in Bronchopulmonary Carcinoids. Endocrine Pathology, 2010, 21, 204-205.	5.2	2
267	Gastritis OLGAâ€staging and gastric cancer risk: a twelveâ€year clinicoâ€pathological followâ€up study. Alimentary Pharmacology and Therapeutics, 2010, 31, 1104-1111.	1.9	191
268	Programmed cell death 4 protein in esophageal cancer. Oncology Reports, 2010, 24, 135-9.	1.2	41
269	BRAF in primary and recurrent papillary thyroid cancers: the relationship with 1311 and 2-[18F]fluoro-2-deoxy-d-glucose uptake ability. European Journal of Endocrinology, 2010, 163, 659-663.	1.9	55
270	Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis. Journal of Clinical Pathology, 2010, 63, 692-696.	1.0	34

#	Article	IF	CITATIONS
271	Aurora kinase A in Barrett's carcinogenesis. Human Pathology, 2010, 41, 1380-1386.	1.1	29
272	Hepatic spleen nodules (HSN). Scandinavian Journal of Gastroenterology, 2010, 45, 628-632.	0.6	18
273	Abstract 3050: MicroRNA expression profiling of human Barrett's carcinogenesis. Cancer Research, 2010, 70, 3050-3050.	0.4	3
274	Antibodies against Synthetic Deamidated Gliadin Peptides for Celiac Disease Diagnosis and Follow-Up in Children. Clinical Chemistry, 2009, 55, 150-157.	1.5	80
275	OLGA Can Guard the Barn. American Journal of Gastroenterology, 2009, 104, 3099.	0.2	10
276	Restorative proctocolectomy for inflammatory bowel disease. International Journal of Colorectal Disease, 2009, 24, 1049-1057.	1.0	4
277	MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. Journal of Pathology, 2009, 219, 214-221.	2.1	449
278	Intestinal or gastric? The unsolved dilemma of Barrett's metaplasia. Human Pathology, 2009, 40, 1206-1207.	1.1	10
279	MicroRNA expression profiling of male breast cancer. Breast Cancer Research, 2009, 11, R58.	2.2	103
280	Prediction of Lymph Node Status in Superficial Esophageal Carcinoma. Annals of Surgical Oncology, 2008, 15, 3278-3288.	0.7	245
281	Molecular characteristics in papillary thyroid cancers (PTCs) with no ¹³¹ 1 uptake. Clinical Endocrinology, 2008, 68, 108-116.	1.2	117
282	OLGA staging for gastritis: A tutorial. Digestive and Liver Disease, 2008, 40, 650-658.	0.4	258
283	Gastric precancerous lesions. Digestive and Liver Disease, 2008, 40, 488-489.	0.4	0
284	Clinical Relevance of Helicobacter pylori cagA and vacA Gene Polymorphisms. Gastroenterology, 2008, 135, 91-99.	0.6	337
285	Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncology, The, 2008, 9, 543-549.	5.1	284
286	Barrett's Esophagus: Still Much to Learn, But "Yes, We Can!― American Journal of Gastroenterology, 2008, 103, 2944-2946.	0.2	6
287	OLGA Gastritis Staging in Young Adults and Country-Specific Gastric Cancer Risk. International Journal of Surgical Pathology, 2008, 16, 150-154.	0.4	35
288	Bronchopulmonary Carcinoid: Phenotype and Long-term Outcome in a Single-Institution Series of Italian Patients. Clinical Cancer Research, 2008, 14, 149-154.	3.2	59

#	Article	IF	CITATIONS
289	Helicobacter pylori, inflammation, oxidative damage and gastric cancer: a morphological, biological and molecular pathway. European Journal of Cancer Prevention, 2008, 17, 195-200.	0.6	71
290	Micronuclei and broken eggs in human liver carcinogenesis. Anticancer Research, 2008, 28, 2507-11.	0.5	11
291	Secondary prevention of gastric cancer. Gut, 2007, 56, 1646-1647.	6.1	19
292	Indefinite for non-invasive neoplasia lesions in gastric intestinal metaplasia: the immunophenotype. Journal of Clinical Pathology, 2007, 60, 615-621.	1.0	24
293	Gastritis staging in clinical practice: the OLGA staging system. Gut, 2007, 56, 631-636.	6.1	370
294	The Veneto Region's Barrett's Oesophagus Registry: Aims, methods, preliminary results. Digestive and Liver Disease, 2007, 39, 18-25.	0.4	25
295	Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma. Journal of Viral Hepatitis, 2007, 14, 821-829.	1.0	49
296	The Potential of Restaging in the Prediction of Pathologic Response After Preoperative Chemoradiotherapy for Rectal Cancer. Annals of Surgical Oncology, 2007, 14, 455-461.	0.7	125
297	Usefulness of Serum Pepsinogens in Helicobacter pylori Chronic Gastritis: Relationship With Inflammation, Activity, and Density of the Bacterium. Digestive Diseases and Sciences, 2006, 51, 1791-1795.	1.1	50
298	Assessing risks for gastric cancer: New tools for pathologists. World Journal of Gastroenterology, 2006, 12, 5622.	1.4	17
299	Non-invasive neoplasia of the stomach. European Journal of Gastroenterology and Hepatology, 2005, 17, 1191-1196.	0.8	30
300	Recovery of gastric function after Helicobacter pylori eradication in subjects with body atrophic gastritis: Prospective 4-year study. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1661-1666.	1.4	6
301	Microsatellite instability and gastric non-invasive neoplasia in a high risk population in Cesena, Italy. Journal of Clinical Pathology, 2005, 58, 805-810.	1.0	19
302	Staging and grading of chronic gastritis. Human Pathology, 2005, 36, 228-233.	1.1	219
303	Pro- and anti-inflammatory cytokines gene polymorphisms and infection: interactions influence outcome. Cytokine, 2005, 29, 141-152.	1.4	184
304	Staging Gastritis: An International Proposal. Gastroenterology, 2005, 129, 1807-1808.	0.6	154
305	Liver Biopsy Sampling in Chronic Viral Hepatitis. Seminars in Liver Disease, 2004, 24, 89-97.	1.8	174
306	Gastric precancerous lesion follow up based on pathological evidence. Journal of Clinical Pathology, 2004, 57, 1007-1008.	1.0	0

#	Article	IF	CITATIONS
307	Serological Markers for Gastric Atrophy in Asymptomatic Patients Infected with Helicobacter pylori. American Journal of Gastroenterology, 2004, 99, 1910-1915.	0.2	40
308	Liver Transplantation for the Treatment of Moderately or Well-Differentiated Hepatocellular Carcinoma. Annals of Surgery, 2004, 239, 150-159.	2.1	289
309	Re: CDX2 Homeotic Gene Expression in Gastric Noninvasive Neoplasia. American Journal of Surgical Pathology, 2004, 28, 834-835.	2.1	115
310	Re: CDX2 homeotic gene expression in gastric noninvasive neoplasia. American Journal of Surgical Pathology, 2004, 28, 834-5; author reply 835.	2.1	15
311	Helicobacter pylori CagA Status, Mucosal Oxidative Damage and Gastritis Phenotype: A Potential Pathway to Cancer?. Helicobacter, 2003, 8, 227-234.	1.6	66
312	What have we learnt from gastric biopsy?. Alimentary Pharmacology and Therapeutics, 2003, 17, 68-74.	1.9	13
313	The long term outcome of gastric non-invasive neoplasia. Gut, 2003, 52, 1111-1116.	6.1	167
314	Atrophic gastritis: pathology and endoscopy in the reversibility assessment. Gut, 2003, 52, 1387-a-1388.	6.1	24
315	Pathology and cost effectiveness of endoscopy surveillance for premalignant gastric lesions. Gut, 2003, 52, 453-454.	6.1	9
316	Fibrosis in Chronic Hepatitis C Acquired in Infancy: Is It Only a Matter of Time?. American Journal of Gastroenterology, 2003, 98, 660-663.	0.2	121
317	Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut, 2002, 50, 697-700.	6.1	65
318	VIRULENCE GENES AND HOST AND \hat{l}^2 GENES INTERPLAY IN FAVOURING THE DEVELOPMENT OF PEPTIC ULCER AND INTESTINAL METAPLASIA. Cytokine, 2002, 18, 242-251.	1.4	72
319	Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Alimentary Pharmacology and Therapeutics, 2002, 16, 1249-1259.	1.9	306
320	Pre-neoplastic states of the gastric mucosa-a practical approach for the perplexed clinician. Alimentary Pharmacology and Therapeutics, 2001, 15, 43-50.	1.9	25
321	Morphometric assessment of gastric antral atrophy: comparison with visual evaluation. Histopathology, 2001, 39, 235-242.	1.6	39
322	Fez1/lzts1 alterations in gastric carcinoma. Clinical Cancer Research, 2001, 7, 1546-52.	3.2	41
323	The p53 gene in patients under the age of 40 with gastric cancer: mutation rates are low but are associated with a cardiac location. Journal of Clinical Pathology, 2000, 53, 207-210.	2.1	32
324	Gastric Dysplasia. American Journal of Surgical Pathology, 2000, 24, 167-176.	2.1	343

#	Article	IF	CITATIONS
325	Topographic patterns of intestinal metaplasia and gastric cancer. American Journal of Gastroenterology, 2000, 95, 1431-1438.	0.2	221
326	Gastric precancerous lesions: heading for an international consensus. Gut, 1999, 45, i5-i8.	6.1	46
327	Microsatellite instability and/or loss of heterozygosity in young gastric cancer patients in Italy. , 1999, 82, 59-62.		19
328	Microsatellite instability and gastric cancer subtypes. Human Pathology, 1999, 30, 108-109.	1.1	3
329	Origin of spurious multiple bands in the amplification of microsatellite sequences. Journal of Clinical Pathology, 1999, 52, 50-51.	2.1	36
330	Helicobacter pylori and Gastric Cancer: Both Primary and Secondary Preventive Measures Are Required. Archives of Internal Medicine, 1999, 159, 2483-2484.	4.3	8
331	Patients younger than 40 years with gastric carcinoma: Helicobacter pylori genotype and associated gastritis phenotype. Cancer, 1999, 85, 2506-11.	2.0	37
332	Oxidative DNA damage accumulation in gastric carcinogenesis. Gut, 1998, 42, 351-356.	6.1	235
333	Loss of FHIT expression in gastric carcinoma. Cancer Research, 1998, 58, 4708-14.	0.4	75
334	Diagnosis of gastric carcinoma in Japan and western countries. Lancet, The, 1997, 350, 448.	6.3	12
335	Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. Journal of Hepatology, 1996, 24, 301-307.	1.8	78
336	Gastric Juice Polymerase Chain Reaction: An Alternative to Histology in the Diagnosis of Helicobacter pylori Infection. Helicobacter, 1996, 1, 159-164.	1.6	20
337	Helicobacter pylori in promotion of gastric carcinogenesis. Digestive Diseases and Sciences, 1996, 41, 950-955.	1.1	61
338	Helicobacter pylori infection enhances mucosal interleukin-1β, interleukin-6, and the soluble receptor of interleukin-2. International Journal of Clinical and Laboratory Research, 1996, 26, 207-210.	1.0	100
339	Gastric Antioxidant, Nitrites, and Mucosal Lipoperoxidation in Chronic Gastritis and Helicobacter pylori Infection. Journal of Clinical Gastroenterology, 1996, 22, 275-281.	1.1	79
340	Loss of heterozygosity for chromosome 11 in adenocarcinoma of the stomach. Cancer Research, 1996, 56, 268-72.	0.4	66
341	Helicobacter pylori serology in patients with chronic gastritis. American Journal of Gastroenterology, 1996, 91, 954-8.	0.2	60
342	Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Research, 1996, 56, 978-83.	0.4	85

#	Article	IF	CITATIONS
343	Gastric epithelial dysplasia. How clinicopathologic background relates to management. Cancer, 1995, 76, 376-382.	2.0	67
344	p53 Overexpression in the Multistep Process of Esophageal Carcinogenesis. American Journal of Surgical Pathology, 1995, 19, 1418-1422.	2.1	57
345	Pathology and ploidy in the prognosis of gastric cancer with no extranodal metastasis. Cancer, 1994, 73, 1127-1133.	2.0	36
346	Gastric epithelial dysplasia in the natural history of gastric cancer: A multicenter prospective follow-up study. Gastroenterology, 1994, 107, 1288-1296.	0.6	240
347	p53 alteration in gastric precancerous lesions. American Journal of Pathology, 1994, 144, 511-7.	1.9	162
348	Treatment of chronic hepatitis C with recombinant human interferon-alpha 2a: results of a randomized controlled clinical trial. Hepatology, 1994, 19, 1-5.	3.6	29
349	Pathology of the gastric antrum and body associated with Helicobacter pylori infection in non-ulcerous patients: is the bacterium a promoter of intestinal metaplasia?. Histopathology, 1993, 22, 9-16.	1.6	71
350	Early and Advanced Gastric Cancer in the Follow-Up of Moderate and Severe Gastric Dysplasia Patients. A Prospective Study. Endoscopy, 1993, 25, 261-264.	1.0	91
351	A randomized controlled trial of lymphoblastoid interferon-Î \pm in patients with chronic hepatitis B lacking HBeAg. Hepatology, 1992, 15, 584-589.	3.6	162
352	Gastric epithelial dysplasia: A prospective multicenter follow-up study from the interdisciplinary group on gastric epithelial dysplasia. Human Pathology, 1991, 22, 1002-1008.	1.1	91
353	Delta Virus and Childhood Leukemia. Pediatric Hematology and Oncology, 1991, 8, 23-32.	0.3	10
354	Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology, 1986, 6, 167-171.	3.6	278
355	Advanced gastric cancer and prognosis. Virchows Archiv A, Pathological Anatomy and Histopathology, 1985, 406, 213-221.	1.4	24
356	Is Mild Gastric Epithelial Dysplasia an Indication for Follow-Up?. Journal of Clinical Gastroenterology, 1983, 5, 307-310.	1.1	20
357	Gastric Epithelial Dysplasia and Sulphomucin-Type Intestinal Metaplasia. Tumori, 1983, 69, 355-357.	0.6	4
358	Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis Gut, 1982, 23, 270-275.	6.1	186
359	Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junction. Gut, 0, , gutjnl-2022-327281.	6.1	13